← Back to Search

Antiviral

INV-102 Eyedrops for Pink Eye

Phase 2
Recruiting
Research Sponsored by Invirsa, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Do you have moderate to sever redness in your eye?
Are you experiencing some discharge in your infected eye?
Timeline
Screening 1 day
Treatment Varies
Follow Up 7 days
Awards & highlights

Summary

"This trial will test new eyedrops called INV-102 on people with Acute Infectious Keratoconjunctivitis. Participants will use the eyedrops for one week and then come back for a

Who is the study for?
Adults over 18 with moderate redness and at least mild discharge in one eye, diagnosed with Acute Infectious Keratoconjunctivitis (AIK), commonly known as pink eye. Participants should not have other conditions that would exclude them from the study.Check my eligibility
What is being tested?
The trial is testing INV-102 eyedrops against a placebo (vehicle) to see if they're effective for treating AIK. It's a phase 2 study where participants are randomly chosen to receive either the test medication or placebo for one week.See study design
What are the potential side effects?
Possible side effects of INV-102 may include irritation at the application site, increased tearing, itching, or redness. Since it's an ophthalmic solution, systemic side effects are less likely but can't be ruled out.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 1 day
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 1 day for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To Evaluate the Change in Combined Clinical Score
Secondary outcome measures
To Evaluate the Percent of participants requiring rescue

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: INV-102 0.7% Three Times per Day (TID)Experimental Treatment1 Intervention
INV-102 ophthalmic solution administered for about 1 week
Group II: Vehicle TIDPlacebo Group1 Intervention
INV-102 ophthalmic solution administered for about 1 week
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INV-102
2022
Completed Phase 2
~90

Find a Location

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

Invirsa, Inc.Lead Sponsor
2 Previous Clinical Trials
194 Total Patients Enrolled
Biomedical Advanced Research and Development AuthorityFED
85 Previous Clinical Trials
540,474 Total Patients Enrolled
~49 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top